Characterization of drug-resistant influenza a(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 249-257

  Marjuki, Henju ^a   Mishin, Vasiliy P ^a   Chesnokov, Anton P ^a,b   Jones, Joyce ^a   De La Cruz, Juan A ^a,b   Sleeman, Katrina ^a   Tamura, Daisuke ^a,c   Nguyen, Ha T ^a,b   Wu, Ho Sheng ^d   Chang, Feng Yee ^d   Liu, Ming Tsan ^d   Fry, Alicia M ^a   Cox, Nancy J ^a   Villanueva, Julie M ^a   Davis, Charles T ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

E119V; ferrets; H7N9; I222K; I222R; influenza virus; mice; oseltamivir; peramivir; R292K

Indexed keywords

A 315675; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; MUTANT PROTEIN; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; FEMALE; HUMAN; INFLUENZA A; INFLUENZA VIRUS A H7N9; MALE; MORTALITY; MOUSE; NONHUMAN; TAIWAN; UPPER RESPIRATORY TRACT; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FERRET; GENETICS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; VIROLOGY; VIRUS CULTURE;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FERRETS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTANT PROTEINS; MUTATION, MISSENSE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; VIRAL PROTEINS; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84922553474     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu447     Document Type: Article

References (46)

1. WHO. Number of confirmed human cases of avian influenza A(H7N9) reported to WHO. http://www.who.int/influenza/human-Animal-interface/influenza-h7n9/14-ReportWebH7N9Number-20140228. pdf?ua=1. Accessed 11 March 2014.
2. WHO. Human infection with avian influenza A(H7N9) virus-update 2014. http://www.who.int/csr/don/archive/year/2014/en/index.html. Accessed 11 March 2014.
3. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
4. LiQ, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014; 370:520-32.
5. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013; 381:1916-25.
6. Marty FM, Man CY, Van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-Arm, phase II study. J Infect Dis 2014; 209:542-50.
7. Sugaya N, Ohashi Y. Long-Acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-82.
8. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10:123-43.
9. Su CT-T, Ouyang X, Zheng J, Kwoh C-K. Structural analysis of the novel influenza A(H7N9) viral neuraminidase interactions with current approved neuraminidase inhibitors oseltamivir, zanamivir, and peramivir in the presence of mutation R289K. BMC Bioinformatics 2013; 14 (Suppl 16):S7.
10. Chang SY, Lin PH, Tsai JC, Hung CC, Chang SC. The first case of H7N9 influenza in Taiwan. Lancet 2013; 381:1621.
11. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-9.
12. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 19:1521-4.
13. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72:2456-62.
14. Mok CK, Chang SC, Chen GW, et al. Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus. J Microbiol Immunol Infect 2013; S1684-1182(13) 00201-6.
15. Lin PH, Chao TL, Kuo SW, et al. Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan. Clin Infect Dis 2014; 58:242-6.
16. Qi Y, Fan H, Qi X, et al. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. Virus Res 2014; 179:119-24.
17. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza Aviruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
18. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010; 54: 1834-41.
19. Piralla A, Gozalo-Marguello M, Fiorina L, et al. Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy. J Clin Virol 2013; 58:132-7.
20. Hurt AC, Leang SK, Tiedemann K, et al. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient. Influenza Other Respir Viruses 2013; 7:904-8.
21. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52:432-7.
22. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54:99-111.
23. Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012; 17:159-73.
24. Abed Y, Pizzorno A, Bouhy X, Rheaume C, Boivin G. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol 2014; 88:1652-8.
25. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010; 201:740-5.
26. Memoli MJ, Davis AS, Proudfoot K, et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2011; 203:348-57.
27. Seibert CW, Kaminski M, Philipp J, et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010; 84:11219-26.
28. Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio 2013; 4. pii: e00396-13.
29. Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013; 501:551-5.
30. Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4:2854.
31. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrugresistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-61.
32. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53:4433-40.
33. Richard M, Ferraris O, Erny A, et al. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011; 55:2942-52.
34. Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, Boivin G. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol 2011; 49:715-7.
35. Kageyama T, Fujisaki S, Takashita E, et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18:20453.
36. Mok CK, Lee HH, Lestra M, et al. Amino acid substitutions in polymerase basic protein 2 gene contribute to the pathogenicity of the novel A/H7N9 influenza virus in mammalian hosts. J Virol 2014; 88:3568-76.
37. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001; 293:1840-2.
38. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012; 87:369-74.
39. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-25.
40. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303:41-4.
41. Wu Y, Bi Y, Vavricka CJ, et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013; 23:1347-55.
42. Yen HL, Zhou J, Choy KT, et al. The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. J Infect Dis 2014; 210:1900-8.
43. Zhao G, Liu C, Kou Z, et al. Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models. PLoS One 2014; 9:e92987.
44. Tang Y, Zhong G, Zhu L, et al. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J Immunol 2010; 184: 5777-90.
45. Zhao C, Hsiang TY, Kuo RL, Krug RM. ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. Proc Natl Acad Sci U S A 2010; 107:2253-8.
46. Zhang S, Wang Q, Wang J, Mizumoto K, Toyoda T. Two mutations in the C-Terminal domain of influenza virus RNA polymerase PB2 enhance transcription by enhancing cap-1 RNA binding activity. Biochim Biophys Acta 2012; 1819:78-83.